Combining catheter ablation and left atrial appendage occlusion in high-risk patients with atrial fibrillation: a

Ziyong Hao1, Bin Liu1, Xiaoyi Xie2

  • 1Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Insights

Combining catheter ablation (CA) with left atrial appendage occlusion (LAAO) is safe for atrial fibrillation (AF) patients. This approach may reduce heart failure hospitalizations, though it increases peri-device leaks.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Electrophysiology

Background:

  • The combined safety and efficacy of catheter ablation (CA) and left atrial appendage occlusion (LAAO) versus LAAO alone for atrial fibrillation (AF) patients is not well-established.
  • Patients with AF and increased stroke risk undergoing LAAO were evaluated.

Purpose of the Study:

  • To compare the safety and efficacy of a combined CA and LAAO approach versus LAAO alone in AF patients.
  • To assess a composite endpoint including death, thromboembolic events, major bleeding, heart failure (HF) rehospitalization, and periprocedural complications.

Main Methods:

  • A total of 707 AF patients undergoing LAAO were analyzed.
  • Propensity score matching created two groups: LAAO alone (83 patients) and combined CA and LAAO (83 patients).
  • The primary endpoint was a composite of death, thromboembolic events, major bleeding, HF rehospitalization, and major periprocedural complications, with a median follow-up of 2 years.

Main Results:

  • Successful LAAO was achieved in all patients, with similar low periprocedural complication rates (2.4% vs. 4.8%).
  • Peri-device leak was significantly higher in the combined group (25.3% vs. 43.4%, p=0.01).
  • No significant difference was observed in the primary composite endpoint between groups (22.2% vs. 14.3%, p=0.63), but HF rehospitalization was significantly lower in the combined group (19.6% vs. 3.6%, p=0.024).

Conclusions:

  • A combined CA and LAAO "one-stop" approach is safe for AF patients.
  • This combined strategy offers additional benefits in reducing heart failure symptoms and hospitalizations.
  • Increased incidence of peri-device leak is a consideration when combining CA and LAAO.
Abstract

Related Concept Videos

Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...